

UBS Equity Biotech Q-acc

Fund Fact Sheet

UBS Equity Funds > UBS Sector Funds

Fund description

- Actively managed equity portfolio investing worldwide in biotech companies.
- Efficient means of exploiting the potential of biotech companies operating in research, product development, production or distribution.
- Specialised sector analysts seek out the most attractive stocks in the biotech sector worldwide.
- Investment decisions are based on a disciplined investment philosophy and fundamental research.


For further information, please see the Key Investor Information Document (KIID) available at: www.ubs.com/espanafondos.

Name of fund	UBS (Lux) Equity Fund - Biotech (USD)
Share class	UBS (Lux) Equity Fund - Biotech (USD) Q-acc
ISIN	LU0400035332
Bloomberg	UBSBIQA LX
Currency of fund / share class	USD/USD
Launch date	12.11.2012
Issue/redemption	daily
Swing pricing	yes
Accounting year end	30 November
Benchmark	MSCI US Investable Market Biotechnology 10/40 Index (r)
Distribution	Reinvestment
Management fee p.a.	0.82%
Entry charge (max.)	5.00%
Exit charge (max.)	0.00%
Conversion fee (max.)	5.00%
Performance fee	none
Ongoing charges p.a.	1.08%
Name of the Management Company	UBS Fund Management (Luxembourg) S.A.
Fund domicile	Luxembourg



A category 1 rating should not be construed as indicating that the investment is free of any risk.

Performance (basis USD, net of fees)¹



Past performance is not a reliable indicator of future results.

in %	1 year	3 years	5 years	Ø p.a. 3 years	Ø p.a. 5 years
Fund (USD)	33.67	20.91	31.56	6.53	5.64
Ref. Index ²	36.09	25.75	40.99	7.94	7.11

The performance shown does not take account of any commissions, entry or exit charges.

- 1 These figures refer to the past. Source for all data and charts (if not indicated otherwise): UBS Asset Management
2 Reference Index in currency of share class (without costs)

Fund statistics

Net asset value (USD, 31.08.2020)	313.62
Last 12 months (USD) – high	345.14
– low	219.11
Total fund assets (USD m)	1 030.12
Share class assets (USD m)	110.46

	3 years	5 years
Beta	0.98	0.98
Volatility ¹		
– Fund	22.28%	24.76%
– Benchmark	22.46%	24.85%
Sharpe ratio	0.21	0.15
Risk free rate	1.78%	1.36%

1 Annualised standard deviation

For more information

Phone: +34-917-457 000
Internet: www.ubs.com/espanafondos
Contact your client advisor

Portfolio management representatives

Nathalie Lötscher Petrus
Matthew Konosky
Florian Töpfl

Before making any investment decisions, we recommend that you read the Key Investor Information Document (KIID) and Prospectus, which are available at: www.ubs.com/espanafondos.

UBS Equity Biotech Q-acc

Market exposure (%)

	Fund
United States	86.07
Denmark	4.43
Canada	2.90
Switzerland	1.96
Netherlands	1.46
United Kingdom	1.33
Germany	1.14
Belgium	0.52
Global	0.19

10 largest equity positions (%)

	Fund
AbbVie Inc	9.73
Vertex Pharmaceuticals Inc	9.66
Seattle Genetics Inc	5.18
Amgen Inc	5.05
Incyte Corp	4.70
Gilead Sciences Inc	4.26
Alnylam Pharmaceuticals Inc	4.17
Regeneron Pharmaceuticals Inc	3.94
Genmab A/S	3.49
BioMarin Pharmaceutical Inc	3.19

Benefits

Easy access to the global biotech sector.
Offers investors broad diversification within the sector.
The fund taps into the knowledge of proven sector specialists.
UBS's proprietary fundamental valuation approach enables the most attractive biotechnology companies to be consistently identified.
Investors benefit from a global investment platform of UBS Asset Management.

Risks

UBS Sector Funds invest in equities and may therefore be subject to high fluctuations in value. For this reason, an investment horizon of at least five years and corresponding risk tolerance and capacity are required. As these UBS Funds pursue an active management style, each Fund's performance can deviate substantially from that of its reference index. Focusing intentionally on individual sectors may entail additional risks. All investments are subject to market fluctuations. Every Fund has specific risks, which can significantly increase under unusual market conditions. The fund can use derivatives, which may result in additional risks (particularly counterparty risk).

Please note that additional fees (e.g. entry or exit fees) may be charged. Please refer to your financial adviser for more details. Investors should read the Key Investor Information Document (KIID), Prospectus and any applicable local offering document prior to investing. For a definition of financial terms refer to the glossary available at www.ubs.com/am-glossary.

For marketing and information purposes by UBS. UBS funds under Luxembourg law. CNMV registration number: UBS (LUX) Equity Fund 148. Representative in Spain for UBS funds established under foreign law: UBS Europe SE, sucursal en España, MARÍA DE MOLINA, 4, E-28006 MADRID. Prospectuses, key investor information (KIID), the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from UBS Europe SE, sucursal en España, MARÍA DE MOLINA Nº 4, E-28006 MADRID / AVENIDA DIAGONAL Nº 640, 2º A, E-08017 BARCELONA / FERNÁNDEZ Y GONZÁLEZ Nº 2, PLANTA PRINCIPAL, E-41001 SEVILLA / C/ROGER DE LAURIA Nº 7, 1ª PLANTA, E-46002 VALENCIA / COSO Nº 33, 5º A, E-50003 ZARAGOZA, CANTÓN PEQUEÑO 15, 4º, E-15003 A CORUÑA. The benchmark is the intellectual property of the index provider. The Share Class is not sponsored or endorsed by the index provider. Please refer to the Fund's prospectus for full disclaimer. Before investing in a product please read the latest prospectus carefully and thoroughly. The fund documentation is available free of charge in English and, where relevant, in one of the local language(s) where the fund is registered. The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document. Members of the UBS Group may have a position in and may make a purchase and / or sale of any of the securities or other financial instruments mentioned in this document. Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming units. Commissions and costs have a negative impact on performance. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This document may not be reproduced, redistributed or republished for any purpose without the written permission of UBS Asset Management Switzerland AG or a local affiliated company. Source for all data and charts (if not indicated otherwise): UBS Asset Management. More explanations of financial terms can be found at ubs.com/am-glossary.
© UBS 2020. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.